Belite Bio's Tinlarebant Shows Strong Secondary Data in Stargardt Disease Trial — Belite Bio, Inc.

Event summary

Belite Bio presented additional positive secondary endpoint data from its Phase 3 DRAGON trial of tinlarebant at the ASRS Annual Meeting on July 18, 2026.
Quantitative autofluorescence (qAF) showed a marked divergence between treatment and placebo groups, with treated subjects showing stable to slightly decreased qAF values.
The Phase 3 DRAGON trial met its primary efficacy endpoint, demonstrating a 35.7% reduction in retinal lesion growth compared to placebo.
Belite Bio completed the New Drug Application for tinlarebant to the U.S. FDA.

The big picture

Belite Bio's positive Phase 3 trial results for tinlarebant position it as a potential first-in-class therapy for Stargardt disease type 1, addressing a significant unmet medical need. The divergence in qAF values between treatment and placebo groups underscores the drug's mechanism of action and reinforces its clinical efficacy. As the company advances through regulatory review, the market awaits the potential approval of tinlarebant, which could set a new benchmark for treating inherited retinal disorders.

What we're watching

Regulatory Approval: The pace at which the U.S. FDA will review and potentially approve tinlarebant for Stargardt disease type 1.
Market Potential: Whether Belite Bio can successfully commercialize tinlarebant, given its status as the first potential therapy for STGD1.
Clinical Development: How the additional secondary endpoint data will influence the ongoing Phase 2/3 DRAGON II and Phase 3 PHOENIX trials for other indications.